• BCECF for pH-Aware Efferocytosis Research

  2026-08-31

  BCECF enables ratiometric extracellular pH measurement in macrophage efferocytosis and neuropathic pain models. This article explains how to use the probe as an orthogonal assay variable without mistaking extracellular acid–base changes for intracellular signaling or pathway proof.

• 4-Hydroxytamoxifen: Practical Protocol Guide

  2026-08-31

  4-Hydroxytamoxifen (SKU B6167) provides a DMSO-compatible estrogen receptor modulator for controlled breast cancer research, prostate cancer research, apoptosis assays, and cardiac myocyte calcium handling studies. It is not appropriate for workflows requiring aqueous or ethanol dissolution, and solutions should not be stored long term.

• Atorvastatin: Mevalonate Pathway to Ferroptosis

  2026-08-30

  Atorvastatin is an HMG-CoA reductase inhibitor with applications spanning cholesterol metabolism research, vascular biology, and ferroptosis-focused hepatocellular carcinoma studies. This guide connects transcriptomic drug discovery with practical assay design while separating established mechanisms from emerging evidence.

• AM 281 for CB1 Cannabinoid Receptor Research

  2026-08-29

  AM 281 enables receptor-level interrogation of CB1 signaling in traumatic brain injury, glutamate homeostasis, and cognitive dysfunction models. This workflow-focused guide connects formulation, time-resolved tissue analysis, behavioral testing, and troubleshooting for more reproducible neuropharmacology experiments.

• Lamotrigine: From Ion Channels to Translation

  2026-08-28

  A translational framework for using Lamotrigine to connect sodium channel biology, serotonin (5-HT) signaling inhibition, epilepsy models, and cardiac sodium current modulation while maintaining rigorous assay and formulation controls.

• BOP Reagent for Prodrug Synthesis and Assay Design

  2026-08-28

  BOP reagent supports controlled carboxyl group activation, amide bond formation, and phenyl ester preparation. This article connects its synthetic utility with assay decisions for ROS-responsive triterpene prodrug research, offering a chemistry-to-biology framework distinct from routine peptide coupling protocols.

• Atorvastatin Workflows for Ferroptosis Research

  2026-08-27

  Atorvastatin is more than a cholesterol biosynthesis inhibitor: it is a practical probe for mevalonate signaling, vascular phenotypes, and ferroptosis-oriented cancer assays. This guide translates the latest hepatocellular carcinoma findings into actionable cell-based workflows, controls, and troubleshooting strategies.

• Fumagillin: From Target to Translational Readout

  2026-08-27

  Fumagillin is a methionine aminopeptidase-2 inhibitor with important implications for angiogenesis research and assay design. This evidence-centered guide explains how to connect molecular targeting, endothelial cell proliferation inhibition, and parasite-screening results without overstating translational relevance.

• Thioguanine Workflows for Cancer and EV71 Research

  2026-08-26

  Build reproducible 6-thioguanine assays by controlling solubility, exposure, cell context, and orthogonal readouts. This practical guide connects cancer cell proliferation inhibition, EV71 virus inhibition, and epigenetic analysis while using the valemetostat phase 1 study as a model for disciplined translational assay design.

• Dynamic Myelin Remodeling After CNS Damage

  2026-08-26

  Arafa and colleagues show that early CNS myelin damage is often marked by swelling that can resolve rather than inevitably progressing to sheath loss. Across zebrafish, rodent, and human MS material, the study links neuronal activity to swelling severity and identifies a potentially actionable window for preserving damaged myelin.

• GDC-0994: Translating ERK1/2 Signals Across Models

  2026-08-25

  GDC-0994 offers a precise way to interrogate ERK1/2 dependence across oncogenic MAP kinase models and estrogen-associated cholestasis. This thought-leadership guide connects pathway biology, experimental design, formulation discipline, and translational decision-making without overstating preclinical evidence.

• Chlorpromazine HCl in Uptake and Neuropharmacology

  2026-08-25

  Chlorpromazine HCl gives researchers a practical pharmacological perturbation for connecting dopamine signaling, membrane trafficking, and nanoparticle uptake assays. Paired with electrical stimulation and orthogonal readouts, it helps distinguish pathway-dependent uptake from nonspecific changes in cell health or particle exposure.

• gamma-Glu-Cys: A Substrate-Centered Assay Strategy

  2026-08-24

  gamma-Glu-Cys is more than a glutathione intermediate: it is a defined experimental boundary for separating enzyme activity from medium and biological context. This article connects glutathione synthetase enzyme assay design with microbial peptide production and plant stress adaptation studies.

• ZK53: From ClpP Activation to Cancer Phenotypes

  2026-08-24

  ZK53 is a human mitochondrial serine protease ClpP activator that connects mitochondrial proteostasis with cancer-cell fate. This article develops a causal framework for interpreting its biochemical, metabolic, DNA-damage, and ferroptosis-related readouts.

• Estradiol Benzoate: ERα Assay Workflows

  2026-08-23

  Estradiol Benzoate provides a practical, high-purity agonist standard for estrogen receptor alpha binding, dose–response, and estrogen receptor signaling research. This guide combines solvent handling, assay design, orthogonal validation, and a careful methodological interpretation of structure-based screening evidence.

8509 records 1/568 page Next 12345 下5页 Last page